

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT2813910

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
CALLIDUS BIOPHARMA, INC.	04/09/2014
RECEIVING PARTY DATA	
Name:	AMICUS THERAPEUTICS, INC.
Street Address:	1 CEDAR BROOK DRIVE
City:	CRANBURY
State/Country:	NEW JERSEY
Postal Code:	08512
PROPERTY NUMBERS Total: 1	
Property Type	Number
Application Number:	13884126
CORRESPONDENCE DATA	
Fax Number:	
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent via US Mail.</i>	
Email:	lmurphy@dsiplaw.com
Correspondent Name:	SERVILLA WHITNEY LLC
Address Line 1:	33 WOOD AVENUE SOUTH
Address Line 2:	SECOND FLOOR, SUITE 210
Address Line 4:	ISELIN, NEW JERSEY 08830
ATTORNEY DOCKET NUMBER:	ACS0022-00US
NAME OF SUBMITTER:	MICHELLE A. CRISTALDI
SIGNATURE:	/Michelle A. Cristaldi, Reg. #66955/
DATE SIGNED:	04/15/2014
Total Attachments: 5	
source=00433947#page1.tif	
source=00433947#page2.tif	
source=00433947#page3.tif	
source=00433947#page4.tif	
source=00433947#page5.tif	

ASSIGNMENT FOR APPLICATIONS FOR PATENT

WHEREAS Callidus Biopharma, Inc., a corporation of the State of Delaware, having a place of business at 3805 Old Easton Road, Doylestown, PA, 18902, United States of America, (hereinafter referred to as Assignor) has rights and title to the patent applications in attached Schedule A:

WHEREAS, Amicus Therapeutics, Inc., a corporation of the State of Delaware, having a place of business at 1 Cedar Brook Drive, Cranbury, NJ 08512, United States of America (hereinafter referred to as Assignee), is desirous of acquiring the entire right, title and interest in and to said applications (hereinafter referred to as the Applications), and the inventions disclosed therein (hereinafter referred to as the Inventions), and in and to all embodiments of the Inventions, and in and to any and all patents, inventor's certificates and other forms of protection (hereinafter referred to as the Patents) thereon granted in any and all countries and groups of countries.

NOW, THEREFORE, in consideration of good and valuable consideration acknowledged by said Assignor to have been received in full from said Assignee, and pursuant to the Agreement and Plan of Merger between Assignor and Assignee dated November 19, 2013:

1. Said Assignor hereby sells, assigns, transfers and conveys to Assignee the full and exclusive right, title and interest (a) in and to said Applications and said Inventions; (b) in and to all rights to apply for patents on said Inventions in any and all countries pursuant to the International Convention for the Protection of Industrial Property or otherwise; (c) in and to any and all Applications filed and any and all Patents granted on said Inventions in any and all countries and groups of countries, including each and every Applications filed and each and every Patent granted on any applications which is a division, substitution, or continuation of said Applications; (d) in and to each and every reissue or extension of any of said Patents; (e) in all income, royalties, and damages now and hereafter due and/or payable to Assignor, including without limitation, damages and payments for past or future infringements and misappropriations thereof; (f) in all rights to sue for past, present and future infringements or misappropriations thereof; and (g) in all rights corresponding to any of the above throughout the world, including the right to claim priority of the US patent applications in patent applications filed in or for any foreign country. The rights, title and interest is to be held and enjoyed by Assignee and Assignee's successors and assigns as fully and exclusively as it would have been held and enjoyed by Assignor had this Assignment not been made, for the full term of any Letters Patent and Registrations which may be granted thereon, or of any division, renewal, continuation in whole or in part, substitution, conversion, reissue, prolongation or extension.

2. Said Assignor agrees that Assignor will, at Assignee's expense, (a) cooperate with Assignee in the prosecution of the foreign counterparts of the Inventions, (b) execute, verify, acknowledge and deliver or possibly deliver all such further papers, including instruments of transfer and (c) perform other such acts as Assignee lawfully may request to obtain or maintain Letters Patent and Registrations for the Inventions in any and all countries, and to vest title

thereto in Assignee, or Assignee's successors and assigns.

3. The term and covenants of this agreement shall inure to the benefit of said Assignee, its successors, assigns and other legal representatives, and shall be binding upon said Assignor, its legal representatives and assigns.

4. Said Assignor hereby warrants and represents that it has not entered and will not enter into any assignment, contract, or understanding in conflict herewith.

IN WITNESS WHEREOF, the said Assignor has executed and delivered this instrument to said Assignee on the Execution Date indicated below.

Assignor:

Daphne Quimi
Daphne Quimi
Chief Financial Officer
Callidus Biopharma, Inc.

Execution Date: April 9 2014

STATE OF New Jersey)
COUNTY OF Mercer)

On this 9th day of April, 2014 before me personally appeared Daphne Quimi to me known and known to me to be the person described in and who executed the foregoing instrument, and he/she duly acknowledged to me that he/she executed the same for the uses and purposes therein set forth.

[SEAL]

Daphne Quimi / MAR 24 3/6/2016
Notary Public
2271760
PUBLIC
EXP. MAR. 6, 2016
NEW JERSEY

Assignee:

Kenneth Peist

Kenneth Peist
Vice President, Legal & Intellectual Property
Amicus Therapeutics, Inc.

Execution Date: April 9, 2014


STATE OF New Jersey)

COUNTY OF Mercer)

On this 9th day of April, 2014 before me personally appeared Kenneth Peist to me known and known to me to be the person described in and who executed the foregoing instrument, and he/she duly acknowledged to me that he/she executed the same for the uses and purposes therein set forth.

[SEAL]

Joseph A. DeLuca 4p 3/6/2016
Notary Public
2271760



SCHEDULE A

<u>REF. NO.</u>	<u>TITLE</u>	<u>APPLICATION #</u>	<u>COUNTRY</u>	<u>FILING DATE</u>
AT-P7000-CA	VARIANT, RECOMBINANT BETA-GLUCOCEREBROSIDASE PROTEINS WITH INCREASED STABILITY AND INCREASED RETAINED CATALYTIC ACTIVITY	2817011	Canada	November 8, 2011
AT-P7000-EP	VARIANT, RECOMBINANT BETA-GLUCOCEREBROSIDASE PROTEINS WITH INCREASED STABILITY AND INCREASED RETAINED CATALYTIC ACTIVITY	11839428.7	EPO	November 8, 2011
AT-P7000-HK	VARIANT, RECOMBINANT BETA-GLUCOCEREBROSIDASE PROTEINS WITH INCREASED STABILITY AND INCREASED RETAINED CATALYTIC ACTIVITY	14102539.8	Hong Kong	November 8, 2011
AT-P7000-KR	VARIANT, RECOMBINANT BETA-GLUCOCEREBROSIDASE PROTEINS WITH INCREASED STABILITY AND INCREASED RETAINED CATALYTIC ACTIVITY	10-2013-7014671	Republic of Korea	November 8, 2011
AT-P7000-US0	VARIANT, RECOMBINANT BETA-GLUCOCEREBROSIDASE PROTEINS WITH INCREASED STABILITY AND INCREASED RETAINED CATALYTIC ACTIVITY	61/412180	USA	November 10, 2010
AT-P7001-US0	VARIANT, RECOMBINANT BETA-GLUCOCEREBROSIDASE PROTEINS WITH INCREASED STABILITY AND INCREASED RETAINED CATALYTIC ACTIVITY	61/411331	USA	November 8, 2010
AT-P7000-US	VARIANT, RECOMBINANT BETA-GLUCOCEREBROSIDASE PROTEINS WITH INCREASED STABILITY AND INCREASED RETAINED CATALYTIC ACTIVITY	13/884126	USA	November 8, 2011
AT-P7000-WO	VARIANT, RECOMBINANT BETA-GLUCOCEREBROSIDASE PROTEINS WITH INCREASED STABILITY AND INCREASED RETAINED CATALYTIC ACTIVITY	PCT/US2011/059731	PCT	November 8, 2011

AT-P7100-CA	NOVEL SIGNAL SEQUENCES TO IMPROVE PROTEIN EXPRESSION AND SECRETION OF RECOMBIANT ENZYMES AND OTHER PROTEINS	2818689	Canada	November 22, 2011
AT-P7100-EP	NOVEL SIGNAL SEQUENCES TO IMPROVE PROTEIN EXPRESSION AND SECRETION OF RECOMBIANT ENZYMES AND OTHER PROTEINS	11843849.8	EPO	November 22, 2011
AT-P7100-EP	NOVEL SIGNAL SEQUENCES TO IMPROVE PROTEIN EXPRESSION AND SECRETION OF RECOMBIANT ENZYMES AND OTHER PROTEINS	14102890.1	Hong Kong	November 22, 2011
AT-P7100-KR	NOVEL SIGNAL SEQUENCES TO IMPROVE PROTEIN EXPRESSION AND SECRETION OF RECOMBIANT ENZYMES AND OTHER PROTEINS	10-2013-7016110	Republic of Korea	November 22, 2011
AT-P7100	NOVEL SIGNAL SEQUENCES TO IMPROVE PROTEIN EXPRESSION AND SECRETION OF RECOMBIANT ENZYMES AND OTHER PROTEINS	61/415926	USA	November 22, 2010
AT-P7100-US	NOVEL SIGNAL SEQUENCES TO IMPROVE PROTEIN EXPRESSION AND SECRETION OF RECOMBIANT ENZYMES AND OTHER PROTEINS	13/988946	USA	November 22, 2011
AT-P7100-WO	NOVEL SIGNAL SEQUENCES TO IMPROVE PROTEIN EXPRESSION AND SECRETION OF RECOMBIANT ENZYMES AND OTHER PROTEINS	PCT/US2011/061862	PCT	November 22, 2011